CD86 and neoplasm: It was determined that DFMO-treated tumors exhibited an increase in F4/80 (macrophage marker), CD86 (a T cell-costimulatory marker) and infiltration of T lymphocytes into the tumor environment as demonstrated by increased CD3, CD4 and CD8 expression in DFMO-treated tumor groups.